PBFT02, developed by Passage Bio, is delivered via intra cisterna magna administration to the brain.
A single patient will be dosed with CRD-THM-001 in an upcoming trial.
The FDA recently accepted the company’s BLA for omidubicel for priority review.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
A recent comparison of health-related quality of life scores also favored ide-cel over belantamab mafodotin treatment.